Launching Jan. 2025: Clinical Readiness Study --
Launching Jan. 2025: Clinical Readiness Study --
We are launching a 2-year, longitudinal clinical readiness study led by Weill Cornell School of Medicine in New York, which is designed to get the MCHS ready for clinical trial under FDA and EMA standards. Stay tuned on Facebook for enrollment information and support our work at the link below!
We are on a mission to find the first-ever drug to tackle MEF2C deficiency.
Join us.
Rare Bird
Advancing MEF2C Therapeutics
rare bird (noun):
an exceptional person or thing; a rarity
Rare Bird is a U.S.-based organization dedicated to advancing and promulgating research that improves the understanding and development of therapeutics for MEF2C Haploinsufficiency Syndrome (MCHS), a rare neurodevelopmental disease that affects 350 children and young adults worldwide.
funding the future
Our team was the largest single funder of MEF2C-focused therapeutics last year. Email us to join the effort.